Key facts
- This page summarizes Gary A. Lyons's Form 4 filing for Travere Therapeutics, Inc. (TVTX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 16 May 2025, 19:00.
Gary A. Lyons - 15 May 2025 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)
- Reporting relationship
- Director
- Issuer ticker
- TVTX
- Reported as of
- 15 May 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 16 May 2025, 19:00:12 UTC
- Prior SEC filing
- 04 Oct 2024
- Next SEC filing
- 22 May 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Elizabeth E. Reed, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Gary A. Lyons filed Form 4 for Travere Therapeutics, Inc. (TVTX) on 16 May 2025.
Change
- Previous filing in this sequence was filed on 04 Oct 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001123343
Primary reporting owner
LYONS GARY A
- Relationship
- Director
- Address
- C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DR., SUITE 300, SAN DIEGO
- Signature
- /s/ Elizabeth E. Reed, Attorney-in-Fact
- Signature date
- 16 May 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TVTX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +6,500
- Change %
- +13%
- Price
- $0.000000
- Shares after
- 57,500
- Date
- 15 May 2025
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TVTX
transaction
Derivative
Stock option (right to buy)
Award
- Transaction value
- $0
- Shares
- +19,500
- Change %
- Price
- $0.000000
- Shares after
- 19,500
- Date
- 15 May 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 19,500
- Exercise price
- $21.15
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.
Footnote F2
The equity award vests over a one year period.